Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (Nasdaq: RXRX) will participate in three upcoming investor conferences, beginning with the Jefferies Global Healthcare Conference London on November 18, 2026.
The company will also participate in the Evercore 9th Annual Healthcare Conference on November 30, 2026, and Citi’s 2026 Global Healthcare Conference on December 1, 2026. Webcasts may be found in the events section at ir.recursion.com.
Portal Innovations and Altitude Lab announced a partnership to relocate Altitude Lab’s accelerator and member startups to Woodbine Labs. Altitude Lab will be the anchor member of the planned 30,000-square-foot Salt Lake City hub, scheduled to open in February 2027. Alumni companies may relocate to graduate suites. Recursion (RXRX), which helped launch Altitude Lab through its charitable foundation, will collaborate on programming and industry engagement.
Recursion (RXRX) reported third-quarter 2026 results, updated clinical trial data and extended its expected cash runway into 2029. The runway includes October offering proceeds. Cash operating expense guidance remains below $375 million for 2026, with below $360 million guided for 2027.
After 12 weeks of REC-4881 treatment, 13 of 15 patients had reduced total polyp burden, with a 47% median reduction. Twelve weeks off treatment, 11 of 13 evaluable patients remained below baseline. REC-1245 produced two confirmed and one unconfirmed partial responses at doses of at least 45 mg, with 91.7% disease control in 12 patients.
Sanofi optioned a development candidate, triggering a $10 million milestone; Sanofi will fund and lead further development. Genentech exercised its first neuroscience Validated Target Option. Fred Hassan became Board Chair effective October 31, 2026.
Recursion (RXRX) reported updated Phase 2 REC-4881 results showing a 47% median reduction in total polyp burden in familial adenomatous polyposis. After 12 weeks of treatment, 13 of 15 patients had reductions; 11 of 13 remained below baseline after 12 weeks off treatment. Median reductions were 55% in the upper gastrointestinal tract and 50% in the lower tract. Six of eight patients had fewer polyps larger than 5 mm, including four with count reductions of at least 80%.
The single-arm, open-label TUPELO trial evaluates an investigational oral treatment. Among 26 safety-evaluable patients, four had Grade 3 treatment-related adverse events; none had Grade 4 or 5 events. Four discontinued for Grade 1 or 2 treatment-related events, with no additional discontinuations since the previous cutoff. Recursion anticipates starting a registrational trial in the second half of 2027, pending ongoing FDA discussions.
Recursion (RXRX) appointed Fred Hassan as chair of its board of directors, effective October 31, 2026, succeeding Rob Hershberg.
Hershberg will continue serving on the board. Hassan brings more than four decades of pharmaceutical industry experience. He is lead independent director of BridgeBio Pharma, executive chair of pharmaceutical intelligence company Norstella and a director at Warburg Pincus, where he previously served as a partner and managing director. His prior board roles include Amgen and Prometheus Biosciences.
Recursion (RXRX) will host a webinar on November 3, 2026, covering updated REC-4881 data and third-quarter business and financial updates. Results will be released after US markets close on November 2, 2026. The webinar begins at 8:00 am ET, live from the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer annual meeting in Denver.
The program includes a management recap, specialist discussion of familial adenomatous polyposis (FAP), and a patient advocate panel. Recursion expects a regulatory update for REC-4881 by year-end. The call will be broadcast on the company’s X, LinkedIn and YouTube accounts.
Recursion Pharmaceuticals (NASDAQ: RXRX) announced that Sanofi optioned the first development candidate from their research collaboration, triggering a $10 million milestone payment. Total upfront and milestone payments received under the collaboration reached $144 million. The oral small molecule targets two targets implicated in inflammatory disease and has entered Sanofi’s development pipeline.
A phase 1 clinical study is currently planned to begin in 2027. Sanofi will fund and lead further development and commercialization, ending Recursion’s operational requirements for the candidate. Recursion remains eligible for more than $300 million in additional program milestones and double-digit royalties on net product sales if approved. The collaboration has achieved six progress-based milestones across five programs. The $10 million payment will be recognized as revenue in the third quarter of 2026.
Recursion Pharmaceuticals (NASDAQ: RXRX) priced an underwritten Class A common stock offering expected to raise approximately $200 million in gross proceeds. The offering comprises 61,540,000 shares at $3.25 per share, all to be sold by Recursion. Gross proceeds are before underwriting discounts, commissions and estimated offering expenses. Recursion expects the offering to close on or about October 16, 2026, subject to customary closing conditions.
Participating investors included Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest and Driehaus Capital Management, alongside other healthcare specialists and mutual funds. Leerink Partners, Goldman Sachs, Morgan Stanley and Evercore are joint bookrunning managers, which coordinate the offering. Needham & Company is lead manager.
Recursion (RXRX) announced a $200 million underwritten common-stock offering alongside updated clinical results and a development milestone with Sanofi.
REC-4881 produced a 47% median reduction in total gastrointestinal polyp burden after 12 weeks in adults with familial adenomatous polyposis; 85% remained below baseline after 12 weeks off treatment. Upper gastrointestinal median reduction was 55%. REC-1245 showed two confirmed endometrial cancer responses and one unconfirmed liver cancer response, with 91.7% disease control at doses of at least 45 mg. Sanofi optioned a development candidate, triggering a $10 million milestone, and will fund and lead further development. Recursion expects cash runway into 2029 including net offering proceeds. A REC-4881 registrational trial is targeted for the second half of 2027, pending FDA discussions; four patients discontinued due to adverse events.
Tempus AI (TEM) and Recursion Pharmaceuticals (RXRX) have extended their multi-year data license agreement and signed a new RNA foundation model license. The collaboration, first established in 2023, is now extended through November 2029.
As part of the extension, the parties amended the Annual License Fees under their Master Agreement, replacing discretionary license fees potentially totaling $84 million over the next two years with committed payments totaling $42 million over the next three years. Separately, Recursion granted Tempus a non-exclusive, worldwide license to its proprietary RNA sequencing model, “TxFM”, under a new license agreement, supporting both companies’ efforts to apply foundation models to precision medicine.